Navigation Links
Valeant Pharmaceuticals Prices Public Offering Of Common Shares
Date:6/18/2013

LAVAL, Quebec, June 18, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) has priced its previously announced public offering of common shares (the "Offering"). Pursuant to the Offering, the Company will issue 23,529,412 common shares at a price of $85.00 per share, for aggregate gross proceeds of approximately $2.0 billion. The Company will file a final prospectus supplement to its effective shelf registration statement on Form S-3 and will make a similar filing with the securities regulatory authorities in each of the provinces of Canada.  Closing of the Offering is expected to occur on or about June 24, 2013.

The Company has also granted to the underwriters of the Offering an option, exercisable for a period of 30 days following the date of the final prospectus supplement, to purchase additional common shares equal to up to 15% of the common shares initially sold.

The Company intends to use the net proceeds from the Offering, together with debt financing, to fund (i) the consideration of its previously disclosed acquisition (the "Merger") of Bausch + Lomb Holdings Incorporated ("B+L"), (ii) the fees and expenses incurred in connection with the Merger; and (iii) the repayment or retirement of B+L's outstanding debt.  If the Merger were not to close for any reason, the proceeds of the Offering will be used for general corporate purposes, which may include providing working capital, funding capital expenditures or for making one or more future acquisitions.

Goldman, Sachs & Co. will act as sole manager of the Offering outside of Canada and Goldman Sachs Canada Inc. will act as sole manager of the Offering in Canada. 

A copy of the final prospectus supplement and accompanying prospectus relating to the Offering in the United States'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Valeant Pharmaceuticals Announces Public Offering Of Common Shares
2. Valeant Pharmaceuticals Announces Filing Of Preliminary Base Shelf Prospectus
3. Valeant Pharmaceuticals Announces Receipt Of U.S. FDA Complete Response Letter For Efinaconazole
4. Valeant Pharmaceuticals Announces 2013 Annual Meeting Results
5. Valeant Pharmaceuticals To Present At 34th Annual Goldman Sachs Global Healthcare Conference
6. Valeant Pharmaceuticals Announces Resignation of Dr. Laurence Paul from Valeants Board of Directors
7. Valeant Pharmaceuticals To Webcast 2013 Annual Meeting Of Shareholders
8. Valeant Pharmaceuticals International, Inc. Announces Additional Information Regarding Continuance Proposal
9. Valeant Pharmaceuticals Provides Efinconazole Update
10. Valeant Pharmaceuticals Reports 2013 First Quarter Financial Results
11. Actavis Acquires Worldwide Rights for Valeants Metronidazole 1.3% Vaginal Gel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... , 21 de noviembre de 2014 /PRNewswire/ ... ensayos clínicos externalizados y tecnologías eClinical, ha indicado ... de ,seguimiento inteligente, para el seguimiento basado en ... inteligente amplía el concepto del seguimiento basado en ... de las visitas de seguimiento o cambio de ...
(Date:11/22/2014)... -- MEDITE Group acquired by CytoCore, Inc. (OTCBB: CYOE) on ... quarter sales ended September 30, 2014 of $8.7 million ... months ended September 2014 and a $38,000 loss for the ... quarter is usually a seasonable weak period due to the ... many countries worldwide, we are proud to announce record sales ...
(Date:11/22/2014)... 2014 Many power shifts are occurring ... of patients in the biopharmaceutical market is impacting ... than ever, understanding how to effectively acquire, convert, ... essential. According to recent research ... spent about two-thirds of their patient-focused dollars on ...
Breaking Medicine Technology:El 'seguimiento inteligente' consigue un excelente momento 2El 'seguimiento inteligente' consigue un excelente momento 3CytoCore Inc. / MEDITE Cancer Diagnostics, Inc. Reports Record YTD and 3rd Quarter Sales 2CytoCore Inc. / MEDITE Cancer Diagnostics, Inc. Reports Record YTD and 3rd Quarter Sales 3New Report Details Importance of Adopting a "Patient Journey" Framework in Marketing 2
... Dec. 22, 2010 Scott & White Healthcare has ... be the home for a new 143-bed acute care ... Investors and College Station ISD. The ... located at the intersection of Texas Hwy 6 and ...
... 2010 Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) ... meeting with the US Food and Drug Administration (FDA) for ... meeting discussions reinforce our position that we have a path ... Arena,s President and Chief Executive Officer. "Based on guidance we ...
Cached Medicine Technology:Scott & White Finalizes College Station Land Deal 2Arena and Eisai Complete End-of-Review Meeting with FDA for Lorcaserin New Drug Application 2Arena and Eisai Complete End-of-Review Meeting with FDA for Lorcaserin New Drug Application 3Arena and Eisai Complete End-of-Review Meeting with FDA for Lorcaserin New Drug Application 4Arena and Eisai Complete End-of-Review Meeting with FDA for Lorcaserin New Drug Application 5
(Date:11/23/2014)... Columbus, OH (PRWEB) November 23, 2014 ... claims on behalf of Ohio and West Virginia residents ... and other health disorders due to drinking C8 ... Plant In Parkersburg, West Virginia. According to the C8 ... because they either worked or lived in at least ...
(Date:11/22/2014)... November 23, 2014 A new AlignLife ... doors in the downtown Greenville area. Dr. Chelsea Sineath, ... , decided to open her own clinic after working ... with the patients. , AlignLife believes that the ... With a focus on chiropractic care and rehabilitation to ...
(Date:11/22/2014)... November 23, 2014 A classic black prom ... the most famous dress suppliers, has unveiled its new items ... dresses are now offered at a big discount, up to ... offer. , The new black prom dresses, made with ... to meet the needs of all customers, the company provides ...
(Date:11/22/2014)... NY (PRWEB) November 22, 2014 ... Goods Administration (TGA) approved it for use “as ... approved and listed within the Therapeutic Goods (Listing) ... , Kyowa Hakko’s Setria® Glutathione will be ... biotech specialist that sources and imports fine chemicals ...
(Date:11/22/2014)... TX (PRWEB) November 22, 2014 ... (ICS) as the complaint that the individual has ... for voiding. The report “Nocturia – Pipeline Review, ... development for Nocturia, complete with comparative analysis at ... of action (MoA), route of administration (RoA) and ...
Breaking Medicine News(10 mins):Health News:40 C8 Lawsuit Claims Filed By Wright & Schulte LLC Alleged Serious Illness Due To C8 Contaminated Water In Ohio And West Virginia 2Health News:40 C8 Lawsuit Claims Filed By Wright & Schulte LLC Alleged Serious Illness Due To C8 Contaminated Water In Ohio And West Virginia 3Health News:40 C8 Lawsuit Claims Filed By Wright & Schulte LLC Alleged Serious Illness Due To C8 Contaminated Water In Ohio And West Virginia 4Health News:AlignLife of Downtown Greenville is Now Open and Accepting New Patients 2Health News:New Black Prom Dresses from BellasDress.com 2Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 4
... order to realize international health goals aiming to improve ... health rights is crucial. In an editorial published this ... PLoS Medicine editors argue that action on maternal ... resources as much as it does access to basic ...
... as hair, nails, sweat glands and mammary glandsare rare ... States, according to a report in the June issue ... JAMA/Archives journals. "Cutaneous appendageal carcinomas are a rare ... that frequently present a diagnostic challenge," the authors write ...
... reveals that patients with diabetes who are hospitalized ... experience longer time in the hospital and are also ... without diabetes., High blood sugar may cause more severe ... by Dr. Ali Parappil of the Department of Respiratory ...
... study , MONDAY, June 21 (HealthDay News) -- Using ear ... receive cochlear implants, a new study finds. , U.S. researchers ... who received ear tubes before cochlear implants. In 46 (59 ... cochlear implantation surgery. In all the other cases, the ear ...
... seem more likely to develop allergies, asthma, study ... who are born vaginally pick up different bacteria than ... how their immune systems develop, a new study suggests. ... why babies born through cesarean sections appear to be ...
... ancient language provides new insights into the nature of ... study, "Dvandvas, Blocking, and the Associative: The Bumpy Ride ... June 2010 issue of the scholarly journal Language, ... A preprint version is available on line at:, http://lsadc.org/info/documents/2010/press-releases/kiparsky.pdf ...
Cached Medicine News:Health News:Cancers of sweat glands, other skin-related structures may be increasing in United States 2Health News:Ear Tubes Appear to Be Safe Before Cochlear Implantation 2Health News:Delivery Method May Determine the Bacteria Babies Acquire 2Health News:Delivery Method May Determine the Bacteria Babies Acquire 3Health News:The 'bumpy ride' of linguistic change 2
Colloidal Gold Sol, 40 nm - 12 - 15, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
... magnification all glass (1.5x) Gonio lens will ... ease., The 4 mirror lens is the ... dynamic gonioscopy and features : , ... appreciate details previously unattainable with Gonio lenses., ...
Colloidal Gold Sol, 20 nm - 50 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
... The PalmScan P2000 Pachymeter [i.e., PalmScan ... portable,battery operated biometer, which incorporates A-mode ... used to accurately measure the corneal ... human eyes. PalmScan P2000 includes two ...
Medicine Products: